Transdermal scopolamine for reduction of drooling in developmentally delayed children.

Abstract

Ten developmentally delayed children with excessive drooling were randomized in a double-blind, placebo-controlled study to assess the efficacy and safety of transdermal scopolamine. Over half of the patients had a statistically significant reduction in drooling, and one-third had cessation of drooling, while wearing the scopolamine patch. This short-term study supports earlier reports of the safety and efficacy of transdermal scopolamine for reducing excessive drooling in developmentally disabled children.

• Authors: D W Lewis, C Fontana, L K Mehallick, Y Everett
• Journal: Developmental medicine and child neurology (Dev Med Child Neurol) Vol. 36 Issue 6 Pg. 484-6 (Jun 1994) ISSN: 0012-1622 [Print] England
• PMID: 7516297 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Placebos
• Scopolamine

Topics

• Administration, Cutaneous
• Adolescent
• Child
• Developmental Disabilities (complications)
• Double-Blind Method
• Female
• Humans
• Male
• Placebos
• Scopolamine (therapeutic use)
• Sialorrhea (drug therapy, etiology)